Elvitegravir

What is Elvitegravir?

Elvitegravir is a potent antiretroviral medication used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Classified as an integrase inhibitor, it plays a crucial role in modern antiretroviral therapy (ART). Elvitegravir specifically targets the integrase enzyme, a protein essential for HIV replication. It is never prescribed as a standalone treatment but is always part of a comprehensive combination therapy regimen, often found in fixed-dose combinations such as Stribild (Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) and Genvoya (Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). These combinations simplify treatment and improve patient adherence.

How Does it Work?

The mechanism of action of Elvitegravir involves inhibiting the HIV integrase enzyme. After HIV enters a host cell, its genetic material is reverse-transcribed into DNA. For the virus to replicate, this viral DNA must be integrated into the host cell's own DNA – a critical step facilitated by the integrase enzyme. By binding to the active site of the integrase enzyme, Elvitegravir prevents this integration process. This blockade effectively stops the virus from inserting its genetic code into the host cell's nucleus, thereby halting viral replication. This action significantly reduces the patient's viral load and helps to restore or preserve immune function, improving overall health for individuals living with HIV.

Medical Uses

The primary medical use of Elvitegravir is for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg. It is indicated for treatment-naïve individuals as well as those who are virologically suppressed on a stable antiretroviral regimen. It's important to reiterate that Elvitegravir, like other antiretrovirals, does not cure HIV infection. Instead, it effectively manages the virus, preventing its progression and reducing the risk of transmission. Its inclusion in fixed-dose combinations has made it a convenient and effective option for many patients, simplifying complex treatment schedules and promoting better adherence. Regular monitoring of viral load and CD4 cell counts is essential to assess treatment effectiveness.

Dosage

The dosage of Elvitegravir is typically 150 mg once daily, taken orally with food. However, it is almost exclusively administered as part of a fixed-dose combination tablet, such as Stribild or Genvoya. These fixed-dose regimens contain Elvitegravir along with other antiretroviral agents (emtricitabine and tenofovir) and a pharmacokinetic enhancer, cobicistat. Cobicistat is not an antiretroviral itself but boosts Elvitegravir's levels in the body by inhibiting its metabolism, allowing for once-daily dosing. It is crucial for patients to follow their healthcare provider's specific instructions regarding dosage and administration. Missing doses can lead to drug resistance and treatment failure, underscoring the importance of strict adherence.

Side Effects

While generally well-tolerated, Elvitegravir can cause side effects. Common side effects often include:

• Nausea, diarrhea
• Headache, fatigue
• Dizziness

More serious, though less common, side effects can include:

• Kidney or liver problems
• Immune Reconstitution Inflammatory Syndrome (IRIS)
• Bone density loss, changes in body fat distribution

Patients should report any persistent or severe side effects to their healthcare provider promptly. Regular blood tests monitor kidney and liver function.

Drug Interactions

Elvitegravir is metabolized by the cytochrome P450 3A (CYP3A) enzyme system and is co-administered with cobicistat, a potent CYP3A inhibitor. This metabolic pathway makes Elvitegravir susceptible to numerous drug interactions, as medications that induce or inhibit CYP3A can significantly alter its levels. Key interactions include:

• Antacids & Supplements: Certain antacids (e.g., magnesium, aluminum) can reduce Elvitegravir absorption. St. John's Wort can significantly decrease Elvitegravir concentrations.
• Other Antiretrovirals: Co-administration may require dose adjustments or be contraindicated.
• Anticonvulsants: Drugs like carbamazepine can reduce Elvitegravir levels.
• Antimycobacterials: Rifampin can significantly decrease Elvitegravir concentrations.
• Steroids: Inhaled or intranasal fluticasone can lead to increased steroid exposure when taken with Elvitegravir/cobicistat.

It is critical for patients to inform their doctor and pharmacist about all medications they are taking.

FAQ

Is Elvitegravir a cure for HIV?

No, Elvitegravir is an antiretroviral medication that manages the virus, suppresses its replication, and improves immune function. Lifelong treatment is typically required.

Can Elvitegravir be taken alone?

No, it is always administered as part of a fixed-dose combination tablet that includes other antiretroviral drugs and a boosting agent (cobicistat).

What should I do if I miss a dose of Elvitegravir?

Take it as soon as you remember, unless it's almost time for your next dose. Skip the missed dose and continue your regular schedule. Do not double dose. Consistent adherence is vital.

How long do I need to take Elvitegravir?

Treatment with Elvitegravir, as part of an antiretroviral regimen, is typically lifelong. Discontinuation without medical supervision can lead to viral rebound and drug resistance.

Products containing Elvitegravir are available through trusted online pharmacies. You can browse Elvitegravir-based medications at ShipperVIP or Medicenter.

Summary

Elvitegravir stands as a key component in the modern treatment landscape for HIV-1 infection. As an integrase inhibitor, it effectively blocks a critical step in the viral life cycle, leading to significant reductions in viral load and improvements in immune health. Always used in fixed-dose combination therapy, often with a boosting agent, it offers a convenient and powerful option for managing HIV. While generally safe, patients must be aware of potential side effects and significant drug interactions. Close collaboration with healthcare providers and strict adherence to the prescribed regimen are paramount for achieving optimal outcomes and maintaining long-term viral suppression in individuals living with HIV.